KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-11-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1999-4915/6/11/4731 |
| _version_ | 1828530621110026240 |
|---|---|
| author | Natacha Coen Sophie Duraffour Robert Snoeck Graciela Andrei |
| author_facet | Natacha Coen Sophie Duraffour Robert Snoeck Graciela Andrei |
| author_sort | Natacha Coen |
| collection | DOAJ |
| description | Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic and incompletely efficacious. As the majority of tumor cells are latently infected with KSHV, currently marketed antivirals that target the virus lytic cycle have shown inconsistent results in clinic. Nevertheless, lytic replication plays a major role in disease progression and virus dissemination. Case reports and retrospective studies have pointed out the benefit of antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a consequence, potent and selective antivirals are needed. This review focuses on the anti-KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and compounds that do not target the viral DNA polymerase are being discussed. We also cover molecules that target cellular kinases, as well as the potential of new drug targets and animal models for antiviral testing. |
| first_indexed | 2024-12-11T22:25:50Z |
| format | Article |
| id | doaj.art-40cdfd1329d04fb28a379becefc88a7b |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-12-11T22:25:50Z |
| publishDate | 2014-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-40cdfd1329d04fb28a379becefc88a7b2022-12-22T00:48:17ZengMDPI AGViruses1999-49152014-11-016114731475910.3390/v6114731v6114731KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic ReplicationNatacha Coen0Sophie Duraffour1Robert Snoeck2Graciela Andrei3Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, BelgiumRega Institute for Medical Research, KU Leuven, B-3000 Leuven, BelgiumRega Institute for Medical Research, KU Leuven, B-3000 Leuven, BelgiumRega Institute for Medical Research, KU Leuven, B-3000 Leuven, BelgiumKaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic and incompletely efficacious. As the majority of tumor cells are latently infected with KSHV, currently marketed antivirals that target the virus lytic cycle have shown inconsistent results in clinic. Nevertheless, lytic replication plays a major role in disease progression and virus dissemination. Case reports and retrospective studies have pointed out the benefit of antiviral therapy in the treatment and prevention of KSHV-associated diseases. As a consequence, potent and selective antivirals are needed. This review focuses on the anti-KSHV activity, mode of action and current status of antiviral drugs targeting KSHV lytic cycle. Among these drugs, different subclasses of viral DNA polymerase inhibitors and compounds that do not target the viral DNA polymerase are being discussed. We also cover molecules that target cellular kinases, as well as the potential of new drug targets and animal models for antiviral testing.http://www.mdpi.com/1999-4915/6/11/4731KSHVantiviralnucleoside analogDNA polymerase inhibitorslytic cycleganciclovircidofovirfoscarnet |
| spellingShingle | Natacha Coen Sophie Duraffour Robert Snoeck Graciela Andrei KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication Viruses KSHV antiviral nucleoside analog DNA polymerase inhibitors lytic cycle ganciclovir cidofovir foscarnet |
| title | KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication |
| title_full | KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication |
| title_fullStr | KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication |
| title_full_unstemmed | KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication |
| title_short | KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication |
| title_sort | kshv targeted therapy an update on inhibitors of viral lytic replication |
| topic | KSHV antiviral nucleoside analog DNA polymerase inhibitors lytic cycle ganciclovir cidofovir foscarnet |
| url | http://www.mdpi.com/1999-4915/6/11/4731 |
| work_keys_str_mv | AT natachacoen kshvtargetedtherapyanupdateoninhibitorsofvirallyticreplication AT sophieduraffour kshvtargetedtherapyanupdateoninhibitorsofvirallyticreplication AT robertsnoeck kshvtargetedtherapyanupdateoninhibitorsofvirallyticreplication AT gracielaandrei kshvtargetedtherapyanupdateoninhibitorsofvirallyticreplication |